Current issue
Archive
Online first
About the Journal
Editorial Office
Editorial Board
Publisher
Editorial Policies
Ethical standards and procedures
Abstracting and indexing
Reviewers
Honorary Reviewers
Subscription
Contact
Most read articles
Instructions for authors
Article processing charge (APC)
Books and Events
Books
Events
ORIGINAL PAPER
Serum IgG galactosylation in psoriatic arthritis patients undergoing a biological treatment. A preliminary report
Submission date: 2014-06-11
Final revision date: 2014-11-18
Acceptance date: 2014-11-24
Online publication date: 2014-11-30
Publication date: 2014-12-31
Reumatologia 2014;52(6):369-376
KEYWORDS
TOPICS
Assessment of disease activity and quality of life in rheumatic diseasesDiagnostics and imaging in rheumatic diseases
ABSTRACT
Aim of the study: A group of psoriatic arthritis patients (PSA, 11 cases) has undergone a treatment. For each patient two serum samples were collected: before the treatment (sample before) and after the treatment (sample after). Performed investigation aimed to provide an information whether a treatment of the PSA patients improves the galactosylation of IgG N-glycans, which previously was shown for rheumatoid arthritis (RA) patients.
Material and methods: Immunoglobulin G (IgG) was isolated from serum of PSA patients, before and after the treatment, using affinity chromatography on Protein A-Sepharose, and was further analyzed regarding the galactose content, using gas chromatography-mass spectrometry (GC-MS) method and ELISA test, performed with two lectins: Ricinus communis (RCA-I) and Griffonia simplicifolia (GSL-II). Based on ELISA results an agalactosylation factor (AF) was calculated for each before and after IgG sample.
Results: Obtained data regarded galactose content in IgG, AF calculation and estimation of two laboratory indices of inflammation: erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) concentration in serum. Based on statistical methods it was shown that average difference (d) of after and before measures of AF for PSA patients was MedHL = –0.097 (95% CI: –0.49–0.25), which means that applied treatment did not affect AF value for this group of patients in a statistically significant manner (p = 0.2936).
Conclusions: The study demonstrated that, in the contrary to RA patients, IgG galactosylation in PSA patients, undergoing a treatment, showed no statistically significant changes.
Material and methods: Immunoglobulin G (IgG) was isolated from serum of PSA patients, before and after the treatment, using affinity chromatography on Protein A-Sepharose, and was further analyzed regarding the galactose content, using gas chromatography-mass spectrometry (GC-MS) method and ELISA test, performed with two lectins: Ricinus communis (RCA-I) and Griffonia simplicifolia (GSL-II). Based on ELISA results an agalactosylation factor (AF) was calculated for each before and after IgG sample.
Results: Obtained data regarded galactose content in IgG, AF calculation and estimation of two laboratory indices of inflammation: erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) concentration in serum. Based on statistical methods it was shown that average difference (d) of after and before measures of AF for PSA patients was MedHL = –0.097 (95% CI: –0.49–0.25), which means that applied treatment did not affect AF value for this group of patients in a statistically significant manner (p = 0.2936).
Conclusions: The study demonstrated that, in the contrary to RA patients, IgG galactosylation in PSA patients, undergoing a treatment, showed no statistically significant changes.
REFERENCES (25)
1.
Hagen TJ. Recent trends in biomarker research and development. Biochem Anal Biochem 2012; 1: 1-4. .
2.
Parekh RB, Dwek RA, Sutton BJ, et al. Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature 1985; 316: 452-457. .
3.
Furukawa K, Matsuta K, Takeuchi F, et al. Kinetic study of a galactosyltransferase in the B cells of patients with rheumatoid arthritis. Int Immunol 1990; 2: 105-112. .
4.
Gindzienska-Sieskiewicz E, Klimiuk PA, Kisiel DG, et al. The changes in monosaccharide composition of immunoglobulin G in the course of rheumatoid arthritis. Clin Rheumatol 2007; 26: 685-690. .
5.
Mehta AS, Long RE, Comunale MA, et al. Increased levels of galactose-deficient anti-Gal immunoglobulin G in the sera of hepatitis C virus-infected individuals with fibrosis and cirrhosis. J Virol 2008; 82: 1259-1270. .
6.
Galili U, Anaraki F, Thall A, et al. One percent of human circulating B lymphocytes are capable of producing the natural anti-Gal antibody. Blood 1993; 82: 2485-2493. .
7.
Kodar K, Kurtenkov O, Klaamas K. The Thomsen-Friedenreich antigen and Gal-specific human IgG glycoforms: Concanavalin A reactivity and relation to survival of cancer patients. Immunol Invest 2009; 38: 704-717. .
8.
Baenziger JU, Fiete D. Structural determinations of Concanavalin A specificity for oligosaccharides. J Biol Chem 1979; 254: 2400-2407. .
9.
Klaamas K, Kodar K, Kurtenkov O. An increased level of the Concanavalin A – positive IgG in the serum of patients with gastric cancer as evaluated by a lectin enzyme-linked immunosorbent assay (LELISA). Neoplasma 2008; 55: 143-150. .
10.
Kodar K, Stadlmann J, Klaamas K, et al. Immunoglobulin G Fc N-glycan profiling in patients with gastric cancer by LC-ESI-MS: relation to tumor progression and survival. Glycoconj J 2012; 29: 57-66. .
11.
Pasek M, Duk M, Podbielska M, et al. Galactosylation of IgG from rheumatoid arthritis (RA) patients – changes during therapy. Glycoconj J 2006; 23: 463-471. .
12.
Duk M, Jakubiak-Augustyn A, Sokolik R, et al. Effect of Adalimumab treatment of psoriatic arthritis patients (PSA) on galactosylation of serum IgG. A preliminary report. EULAR Meeting 2012; Berlin, 6-9 June, abstract AB 0945. .
13.
Ey PL, Prowse SJ, Jenkin CR. Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-Sepharose. Immunochemistry 1978; 15: 429-436. .
14.
Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685. .
15.
Smith PK, Krohn RI, Hermanson GT, et al. Measurement of protein using bicinchoninic acid. Anal Biochem 1985; 150: 76-85. .
16.
Sawardeker JS, Sloneker JH, Jeanes A. Quantitative determination of monosaccharides as their alditol acetates by liquid chromatography. Anal Chem 1965; 37: 1602-1604. .
17.
Lisowska E, Duk M, Wu AM. Preparation of biotinylated lectins and application in microtiter plate assays and western blotting. Bio Methods 1996; 7: 115-129. .
18.
Rousseeuw PJ, Croux C. Alternatives to the median absolute deviation. JASA 1993; 88: 1273-1283. .
19.
Endo T, Furukawa K. Rheumatoid arthritis and serum IgG. In: Glycoproteins and disease. Montreuil J, Fliegenthart JFG, Schachter H (eds.). 1996; 277-289. .
20.
Watson M, Rudd PM, Bland M, et al. Sugar printing rheumatic diseases: a potential method for disease differentiation using immunoglobulin G oligosaccharides. Arthritis Rheum 1999; 42: 1682-1690. .
21.
Youings A, Chang SC, Dwek RA, Scragg IG. Site-specific glycosylation of human immunoglobulin G is altered in four rheumatoid arthritis patients. Biochem J 1996; 314: 621-630. .
22.
Wormald MR, Rudd PM, Harvey DJ, et al. Variations in oligosaccharide-protein interactions in immunoglobulin G determine the site-specific glycosylation profiles and modulate the dynamic motion of the Fc oligosaccharides. Biochemistry 1997; 36: 1370-1380. .
23.
Croce A, Firuzi O, Altieri F, et al. Effect of Infliximab on the glycosylation of IgG of patients with rheumatoid arthritis. J Clin Lab Anal 2007; 21: 303-314. .
24.
Targońska-Stępniak B, Majdan M, Seweryn R, Kiełbik Z. Adalimumab treatment in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis in therapeutic programmes – personal experience. Reumatologia 2013; 51: 9-14. .
25.
Majdan M, Siwiec A, Gryta A. Certolizumab pegol – new option in the treatment psoriatic arthritis. Reumatologia 2014; 52: 181-188.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Share
RELATED ARTICLE
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
